Ajay Major, Assistant Professor of Medicine at the University of Colorado School of Medicine, shared a post on X:
“From ASH24 oral:
CTCL global QOL scores and pruritis improve in both responders and non-responders (non-responders just have a delayed improvement).
No patients with Sezary had severe CTCL symptoms by week 81!
PRO benefit in both SS and MF.”
